Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Resistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Q
Accès en ligne:https://doaj.org/article/65ef3b7f9a184674b715885b4857dafc
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!